The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.
 
José Manuel Pérez García
Employment - MedSIR
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Roche; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Roche
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Manuel Ruiz-Borrego
Honoraria - Novartis; pfizer; Roche/Genentech
Consulting or Advisory Role - Puma Biotechnology; Roche
 
Agostina Stradella
Consulting or Advisory Role - Novartis; Seagan
Travel, Accommodations, Expenses - Novartis; Novartis
 
Begoña Bermejo
Consulting or Advisory Role - AstraZeneca; MSD; Novartis; Pierre Fabre; Roche; Seagen
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Eisai; MSD; Palex; Pfizer; Roche; Seagen
 
Santiago Escrivá-de-Romaní
Consulting or Advisory Role - Cor2Ed; Daiichi Sankyo/Astra Zeneca; Jazz Pharmaceuticals; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Cor2Ed; Daiichi Sankyo/Astra Zeneca; Novartis; Pfizer; Seagen
Research Funding - Byondis (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Jazz Pharmaceuticals (Inst); medsir (Inst); Roche (Inst); SOLTI (Inst); Synthon (Inst); Zymeworks (Inst)
Expert Testimony - Cor2Ed
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Kern Pharma; Pfizer; Seagen; SOLTI
 
Lourdes Calvo
No Relationships to Disclose
 
Geraldine Gebhart
No Relationships to Disclose
 
Khaldoun Kerrou
No Relationships to Disclose
 
Juan José García-Mosquera
Employment - Trialing Health
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Novartis; Palex; Roche
 
Maria Gion
Consulting or Advisory Role - AstraZeneca; Gilead Sciences
Speakers' Bureau - AstraZeneca; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Gabriele Antonarelli
Honoraria - MedSIR
Travel, Accommodations, Expenses - MedSIR
 
Laura López-Montero
Employment - MedSIR
 
José Rodríguez-Morató
Employment - MedSIR
 
Leonardo Mina
Employment - MedSIR
 
Miguel Sampayo-Cordero
Honoraria - Ability Pharma; MD Anderson Cancer Center; MedSIR; Optimapharm; Syntax for Science
 
Antonio Llombart-Cussac
Stock and Other Ownership Interests - Initia-Research; MAJ3 Capital
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Lilly; MSD; Novartis; Pfizer
Research Funding - Agendia (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1. LICENSED
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer; Roche; Stemline Therapeutics